Stantec

The University of California is planning to construct the UCSF Life Sciences Building as part of a major redevelopment of the former Dogpatch Power Station in San Francisco. The transformative facility will bring research, innovation, primary and specialty care clinics, and world-class cancer treatment to a new waterfront destination. Standing eight stories above ground, the structure will include two basement levels for a state-of-the-art proton therapy center that will begin operations in 2029.

The University of North Texas at Dallas is constructing the $100 million STEM Building to provide current and future students with expanded learning opportunities in the sciences, technology, engineering, and mathematics. Stantec is providing integrated design services for the 128,000-sf facility, which will offer up to 20 general purpose “high-flex” classrooms, nine teaching labs, three research labs, and numerous collaboration spaces. Adaptable wet labs will leverage modular infrastructure to accommodate a variety of biology and chemistry courses.

Bristol Myers Squibb is expanding its Moreton campus in the United Kingdom with the construction of a new facility for pharmaceutical discovery and development. Designed by ADP Architecture, the 38,000-sf building will feature state-of-the-art laboratories, flexible office areas, and dynamic collaboration zones. Next-generation analytical suites will accelerate the commercialization of new treatments for diabetes, high blood pressure, and other conditions.

Agratas, a subsidiary of Tata Group, will break ground in spring of 2024 on a £4 billion battery factory in the United Kingdom. Located on the Gravity Smart Campus in Bridgwater, the three-building complex will leverage highly efficient processes and technologies to produce advanced battery cells for electric vehicles. The sustainable project involves the adaptive reuse of an existing brownfield site and the creation of sophisticated renewable energy systems.

AstraZeneca is partnering with Boston Properties to create a 570,000-sf R&D center in Cambridge’s Kendall Square. Housing approximately 1,850 employees, the 16-story building will offer world-class research environments for the creation of advanced biomedical therapies and vaccines. This nexus of innovation and discovery will feature flexible open laboratories arranged in neighborhoods with shared instrumentation suites and collaboration spaces.